Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
Hyun‐Ah Kim, Jong Won Lee, Seok Jin Nam, et al.
Journal of Clinical Oncology (2019) Vol. 38, Iss. 5, pp. 434-443
Open Access | Times Cited: 75

Showing 26-50 of 75 citing articles:

Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers
Inês Vaz-Luís, Prudence A. Francis, Antonio Di Meglio, et al.
American Society of Clinical Oncology Educational Book (2021), Iss. 41, pp. e47-e61
Open Access | Times Cited: 19
Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up
Jie Ju, Songlin Gao, Jiayu Wang, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 6, pp. 439-447
Open Access | Times Cited: 2
Hormone receptor-positive early breast cancer in young women: A comprehensive review
Benjamín Walbaum, Isabel Garcia‐Fructuoso, Olga Martínez‐Sáez, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102804-102804
Closed Access | Times Cited: 2
Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy
Megan E. Tesch, Yue Zheng, Shoshana M. Rosenberg, et al.
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Nanomaterials: breaking the bottleneck of breast cancer drug resistance
Chao Guan, Yanbing Han, Ling Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Targeting autophagy with tamoxifen in breast cancer: From molecular mechanisms to targeted therapy
Mohammad Yasin Zamanian, Maryam Golmohammadi, Amir Nili‐Ahmadabadi, et al.
Fundamental and Clinical Pharmacology (2023) Vol. 37, Iss. 6, pp. 1092-1108
Closed Access | Times Cited: 6
Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report
Hee Jeong Kim, Woo Chul Noh, Seok Jin Nam, et al.
European Journal of Cancer (2021) Vol. 151, pp. 190-200
Closed Access | Times Cited: 15
CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
Siker Kimbung, Maria Inasu, Tor Stålhammar, et al.
Breast Cancer Research (2020) Vol. 22, Iss. 1
Open Access | Times Cited: 15
Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions
Tal Sella, Kathryn J. Ruddy, Lisa A. Carey, et al.
JCO Oncology Practice (2021) Vol. 18, Iss. 3, pp. 211-216
Open Access | Times Cited: 14
Indoleamine 2,3-dioxygenase 1 regulates breast cancer tamoxifen resistance through interleukin-6/signal transducer and activator of transcription
Xinchun Zhao, Yujia Jiang, Ming Xu, et al.
Toxicology and Applied Pharmacology (2022) Vol. 440, pp. 115921-115921
Open Access | Times Cited: 9
Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer
Richard A. Anderson, Tom Kelsey, Anne Perdrix, et al.
Breast Cancer Research and Treatment (2022) Vol. 192, Iss. 2, pp. 273-282
Open Access | Times Cited: 8
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy
Núria Chic, Francesco Schettini, Fara Brasó‐Maristany, et al.
EBioMedicine (2021) Vol. 69, pp. 103451-103451
Open Access | Times Cited: 11
High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
Maria Inasu, Pär‐Ola Bendahl, Mårten Fernö, et al.
npj Breast Cancer (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 11
Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects
Fatima Khan, Kristin E. Rojas, Matthew Schlumbrecht, et al.
Current Oncology (2023) Vol. 30, Iss. 2, pp. 1794-1804
Open Access | Times Cited: 4
Mammary carcinoma: Comparative oncology between small animals and humans—New therapeutic tools
Jean‐Sébastien Frenel, Frédérique Nguyen
Reproduction in Domestic Animals (2023) Vol. 58, Iss. S2, pp. 102-108
Open Access | Times Cited: 4
Adjuvant Ovarian Function Suppression in Premenopausal Hormone Receptor–Positive Breast Cancer
Robert B. Basmadjian, Sasha Lupichuk, Yuan Xu, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e242082-e242082
Open Access | Times Cited: 1
Patient‐reported outcome and survival in premenopausal hormone receptor‐positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real‐world study
Yaping Yang, Fengxia Gan, Ting Luo, et al.
MedComm (2024) Vol. 5, Iss. 10
Open Access | Times Cited: 1
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer
Francesca Parisi, Maria Grazia Razeti, Eva Blondeaux, et al.
Clinical Medicine Insights Oncology (2020) Vol. 14
Open Access | Times Cited: 8
Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions
Oleg Gluz, Monika Graeser
Current Oncology Reports (2023) Vol. 25, Iss. 5, pp. 491-500
Closed Access | Times Cited: 3
Gonadotropin-Releasing Hormone Agonists during Gonadal Chemotherapy for the Effect on Pregnancy Outcome and Ovarian Function in Premenopausal Patients with Breast Cancer: A Systematic Review and Meta-Analysis
Yuan Yuan, Chu Zhang, Xueli Lei, et al.
Breast Care (2023) Vol. 18, Iss. 4, pp. 270-278
Closed Access | Times Cited: 3
Health-related quality of life of premenopausal young breast cancer survivors undergoing endocrine therapy
Kyungmi Lee, Hye Suk Jun
European Journal of Oncology Nursing (2023) Vol. 68, pp. 102496-102496
Closed Access | Times Cited: 3
Role of Ovarian Suppression in Early Premenopausal Breast Cancer
Prudence A. Francis
Hematology/Oncology Clinics of North America (2022) Vol. 37, Iss. 1, pp. 79-88
Open Access | Times Cited: 5
Cyclophosphamide-Free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women With Breast Cancer
Matteo Lambertini, Ann H. Partridge
JNCI Journal of the National Cancer Institute (2021) Vol. 113, Iss. 10, pp. 1274-1276
Open Access | Times Cited: 6
Measurable Serum Estradiol and Estrone in Women 36-56 Years During Adjuvant Treatment With Aromatase Inhibitors for a Hormone Receptor-Positive Breast Cancer. Case Studies and Cross-sectional Study Using an Ultra-sensitive LC-MS/MS-Method.
Maxime Van Houdt, Sileny Han, Steven Pauwels, et al.
Clinical Breast Cancer (2022) Vol. 23, Iss. 1, pp. 84-90
Closed Access | Times Cited: 4
Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel
Tanja Fehm, Elmar Stickeler, Peter A. Fasching, et al.
Geburtshilfe und Frauenheilkunde (2021) Vol. 81, Iss. 06, pp. 654-665
Open Access | Times Cited: 5

Scroll to top